Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MiNK Therapeutics, Inc. (MiNK Therapeutics) is a publicly traded clinical-stage biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for the treatment of cancer and immune-mediated diseases. The company operates within the biotechnology and cell therapy industries, with a strategic emphasis on off-the-shelf cellular immunotherapies designed to overcome limitations of autologous approaches such as manufacturing complexity and patient variability.
The company’s primary value driver is its proprietary iNKT cell platform, with its lead product candidate agenT-797 (previously known as MiNK-002) under clinical development for oncology indications including solid tumors and hematologic malignancies. MiNK Therapeutics was founded in 2017 and became publicly listed in 2021 through a merger with a special purpose acquisition company, marking its transition from a private research-focused entity to a publicly traded clinical-stage biopharmaceutical company.
Business Operations
MiNK Therapeutics operates as a single-reportable-segment biotechnology company, generating no product revenue and focusing on research and development activities. Its core operations center on the discovery, clinical development, and potential commercialization of allogeneic iNKT cell therapies, leveraging proprietary manufacturing processes and immune modulation technologies designed to enhance anti-tumor activity while reducing toxicity.
The company conducts clinical development primarily in the United States with international clinical trial activity supported through collaborations and clinical sites in Europe. MiNK Therapeutics does not currently report any commercial products or revenue-generating subsidiaries, and its operations are funded through equity financing and cash reserves. Data regarding material joint ventures or revenue-producing partnerships is inconclusive based on available public sources.
Strategic Position & Investments
MiNK Therapeutics’ strategic direction centers on advancing agenT-797 through mid-stage clinical trials while expanding the therapeutic potential of iNKT cell biology across oncology and immune-mediated indications. Growth initiatives focus on clinical validation of its allogeneic platform, potential label expansion, and combination strategies with other immuno-oncology agents.
The company has invested primarily in internal research capabilities and clinical trial infrastructure rather than large-scale acquisitions. No major acquisitions have been publicly disclosed. MiNK Therapeutics maintains a selective collaboration strategy with academic institutions and clinical research organizations. Information regarding undisclosed portfolio investments or emerging technology investments beyond its core iNKT platform is inconclusive based on available public sources.
Geographic Footprint
MiNK Therapeutics is headquartered in the United States, with its principal executive offices located in New York. The company’s operational footprint is primarily North American, supported by international clinical trial activities and research collaborations in Europe, particularly Italy, reflecting the scientific background of its leadership and development teams.
While MiNK Therapeutics does not maintain large-scale international manufacturing or commercial infrastructure, its clinical and regulatory strategy is designed to support future global development. International influence is currently limited to research, development, and clinical trial execution rather than commercial operations.
Leadership & Governance
MiNK Therapeutics is led by an executive team with experience in biotechnology, immunology, and pharmaceutical development. The leadership emphasizes scientific rigor, disciplined capital allocation, and advancing differentiated immunotherapy platforms through clinical proof-of-concept.
Key executives include:
- Alessandro Riva, MD – Chief Executive Officer
- Robert Tillman – Chairman of the Board
- Bo H. Cumbo – Chief Financial Officer
- Marc Daftary, MD – Chief Medical Officer
- Andrea Brancatella, PhD – Chief Scientific Officer
Information regarding additional founders or changes in executive roles has shown minor inconsistencies across public disclosures; however, the above leadership structure is consistently reported in company filings and public investor materials.